BiVictriX Therapeutics plc announced that it has appointed Dr Michael Kauffman, M.D., Ph.D. to its Board of Directors as an Independent Non-Executive Director with effect from 17 January 2022. He currently serves on the Boards of Karyopharm Therapeutics Inc, Verastem Oncology, Kezar Life Sciences and Adicet Bio.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.65 GBX | -2.69% | -2.69% | +20.48% |
06-21 | BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
06-13 | EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss | AN |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.48% | 13.95M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+47.58% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics plc
- BiVictriX Therapeutics plc Announces Appointment of Michael Kauffman as Independent Non-Executive Director